Literature DB >> 3411098

Blood-brain barrier permeability in galactosamine-induced hepatic encephalopathy. No evidence for increased GABA-transport.

G M Knudsen1, H E Poulsen, O B Paulson.   

Abstract

Blood-brain barrier permeability to the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), to sucrose and to sodium was studied in rats with galactosamine-induced liver damage and hepatic encephalopathy by means of an arterial integral uptake technique. Permeability to GABA was unaltered in all examined brain regions (2.47 +/- 0.25.10(-5) cm3.s-1.g-1, mean +/- S.D.) as compared to control rats (2.49 +/- 0.19.10(-5) cm3.s-1.g-1). The permeability to sucrose (galactosamine 0.25 +/- 0.02 vs. controls 0.24 +/- 0.02.10(-5) cm3.s-1.g-1) and to sodium (galactosamine 5.33 +/- 0.04 vs. controls 5.40 +/- 0.05.10(-5) cm3.s-1.g-1) was also unchanged in hepatic encephalopathy. At the time of investigation mean liver function measured by antipyrine clearance was reduced from 0.39 in control rats to 0.23 ml/min/100 g body wt. in galactosamine-treated animals. The present study does not support the suggestion that peripheral GABA penetrates the blood-brain barrier to any higher extent in hepatic encephalopathy. This provides evidence against at least part of the GABA-hypothesis. Furthermore, an unspecific increased blood-brain barrier permeability in hepatic encephalopathy, as measured by sucrose and sodium uptake, was not found. It is concluded that the GABA-theory requires further careful reevaluation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3411098     DOI: 10.1016/s0168-8278(88)80030-8

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  12 in total

Review 1.  Positron emission tomography in the study of hepatic encephalopathy.

Authors:  Alan H Lockwood
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

Review 2.  Neurochemistry of hepatic encephalopathy.

Authors:  C O Record
Journal:  Gut       Date:  1991-11       Impact factor: 23.059

3.  Hyperammonaemia reduces intracellular 22Na (sodium) ion and extracellular 86Rb ion concentrations in the blood-brain barrier of the rat.

Authors:  Barry Alexander; Kevin A Smart; Malcolm B Segal; Jane E Preston
Journal:  Metab Brain Dis       Date:  2005-03       Impact factor: 3.584

4.  Mitochondrial Changes in Rat Brain Endothelial Cells Associated with Hepatic Encephalopathy: Relation to the Blood-Brain Barrier Dysfunction.

Authors:  Krzysztof Milewski; Karolina Orzeł-Gajowik; Magdalena Zielińska
Journal:  Neurochem Res       Date:  2022-08-02       Impact factor: 4.414

5.  TIMP-1/MMP-9 imbalance in brain edema in rats with fulminant hepatic failure.

Authors:  Satoshi Yamamoto; Justin H Nguyen
Journal:  J Surg Res       Date:  2006-02-20       Impact factor: 2.192

6.  Ammonia-induced astrocyte swelling in primary culture.

Authors:  M D Norenberg; L Baker; L O Norenberg; J Blicharska; J H Bruce-Gregorios; J T Neary
Journal:  Neurochem Res       Date:  1991-07       Impact factor: 3.996

7.  GABA Supplementation Negatively Affects Cognitive Flexibility Independent of Tyrosine.

Authors:  Lee Wei Lim; Luca Aquili
Journal:  J Clin Med       Date:  2021-04-21       Impact factor: 4.241

Review 8.  From gut microbiota to host appetite: gut microbiota-derived metabolites as key regulators.

Authors:  Hui Han; Bao Yi; Ruqing Zhong; Mengyu Wang; Shunfen Zhang; Jie Ma; Yulong Yin; Jie Yin; Liang Chen; Hongfu Zhang
Journal:  Microbiome       Date:  2021-07-20       Impact factor: 14.650

Review 9.  Neurotransmitters as food supplements: the effects of GABA on brain and behavior.

Authors:  Evert Boonstra; Roy de Kleijn; Lorenza S Colzato; Anneke Alkemade; Birte U Forstmann; Sander Nieuwenhuis
Journal:  Front Psychol       Date:  2015-10-06

10.  γ-Aminobutyric acid (GABA) administration improves action selection processes: a randomised controlled trial.

Authors:  Laura Steenbergen; Roberta Sellaro; Ann-Kathrin Stock; Christian Beste; Lorenza S Colzato
Journal:  Sci Rep       Date:  2015-07-31       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.